4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers

Background Responses to immunotherapy vary between different cancer types and sites. Here, we aimed to investigate features of exhaustion and activation in tumor-infiltrating CD8 T cells at both the primary and metastatic sites in epithelial ovarian cancer. Methods Tumor tissues and peripheral blood were obtained from 65 patients with ovarian cancer. From these samples, we isolated tumor-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells. These cells were used for immunophenotype using multicolor flow cytometry, gene expression profile using RNA sequencing and ex vivo functional restoration assays. Results We found that CD39+ CD8 TILs were enriched with tumor-specific CD8 TILs, and that the activation status of these cells was determined by the differential programmed cell death protein 1 (PD-1) expression level. CD39+ CD8 TILs with high PD-1 expression (PD-1high) exhibited features of highly tumor-reactive and terminally exhausted phenotypes. Notably, PD-1high CD39+ CD8 TILs showed similar characteristics in terms of T-cell exhaustion and activation between the primary and metastatic sites. Among co-stimulatory receptors, 4-1BB was exclusively overexpressed in CD39+ CD8 TILs, especially on PD-1high cells, and 4-1BB-expressing cells displayed immunophenotypes indicating higher degrees of T-cell activation and proliferation, and less exhaustion, compared with cells not expressing 4-1BB. Importantly, 4-1BB agonistic antibodies further enhanced the anti-PD-1-mediated reinvigoration of exhausted CD8 TILs from both primary and metastatic sites. Conclusion Severely exhausted PD-1high CD39+ CD8 TILs displayed a distinctly heterogeneous exhaustion and activation status determined by differential 4-1BB expression levels, providing rationale and evidence for immunotherapies targeting co-stimulatory receptor 4-1BB in ovarian cancers.

[1]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[2]  L. Landi,et al.  Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer , 2019, Journal of Immunotherapy for Cancer.

[3]  Hualiang Jiang,et al.  Selective activation of TWIK-related acid-sensitive K+ 3 subunit–containing channels is analgesic in rodent models , 2019, Science Translational Medicine.

[4]  S. Berger,et al.  TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.

[5]  J. Werner,et al.  Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer , 2019, Cancers.

[6]  Y. Chung,et al.  Integrative immunologic and genomic characterization of brain metastasis from ovarian/peritoneal cancer. , 2019, Pathology, research and practice.

[7]  D. Welch,et al.  Defining the Hallmarks of Metastasis. , 2019, Cancer research.

[8]  C. Klein,et al.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy , 2019, Science Translational Medicine.

[9]  L. Strigari,et al.  A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab , 2019, Journal of Translational Medicine.

[10]  M. Good,et al.  Challenges and strategies for developing efficacious and long-lasting malaria vaccines , 2019, Science Translational Medicine.

[11]  Hanzi Xu,et al.  Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets , 2019, Journal of Ovarian Research.

[12]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[13]  T. Schumacher,et al.  Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers , 2018, Nature Medicine.

[14]  J. Zapata,et al.  A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity , 2018, Nature Communications.

[15]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[16]  S. Leschka,et al.  Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) , 2018, Cancer Immunology, Immunotherapy.

[17]  B. Fox,et al.  Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors , 2018, Nature Communications.

[18]  A. Hoos,et al.  The promise and challenges of immune agonist antibody development in cancer , 2018, Nature Reviews Drug Discovery.

[19]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.

[20]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[21]  D. Provencher,et al.  Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. , 2018 .

[22]  Young Tae Kim,et al.  Changes in ovarian cancer survival during the 20 years before the era of targeted therapy , 2018, BMC Cancer.

[23]  Jian Yu,et al.  Immunogenic effects of chemotherapy-induced tumor cell death , 2018, Genes & diseases.

[24]  D. Bedognetti,et al.  NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives , 2018, Front. Immunol..

[25]  M. Fehlings,et al.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.

[26]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[27]  Hidekazu Suzuki,et al.  Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial , 2018, PloS one.

[28]  I. Melero,et al.  Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. , 2018, Blood.

[29]  Harini Veeraraghavan,et al.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.

[30]  M. Milano,et al.  Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. , 2017, Journal of thoracic disease.

[31]  C. Morrison,et al.  NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. , 2017, Gynecologic oncology.

[32]  J. Radford Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[33]  S. Rosenberg,et al.  Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression , 2016, Clinical Cancer Research.

[34]  H. Clevers,et al.  Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells , 2016, Nature Immunology.

[35]  R. Levy,et al.  Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody , 2016, Clinical Cancer Research.

[36]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[37]  Yulei N. Wang,et al.  Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) , 2016 .

[38]  Aviv Regev,et al.  A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells , 2016, Cell.

[39]  H. Hollema,et al.  CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. , 2016, European journal of cancer.

[40]  C. Ware,et al.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. , 2016, Immunity.

[41]  H. Streeck,et al.  CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity , 2016, The Journal of Immunology.

[42]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[43]  J. Weon,et al.  The MAGE protein family and cancer. , 2015, Current opinion in cell biology.

[44]  S. Rosenberg,et al.  Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes , 2015, Journal of Immunotherapy for Cancer.

[45]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[47]  Mark Peakman,et al.  More tricks with tetramers: a practical guide to staining T cells with peptide–MHC multimers , 2015, Immunology.

[48]  I. Melero,et al.  Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. , 2015, Seminars in oncology.

[49]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  B. Nelson New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. , 2015, Current opinion in immunology.

[51]  E. Wherry,et al.  Overcoming T cell exhaustion in infection and cancer. , 2015, Trends in immunology.

[52]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[53]  Y. Song,et al.  Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing BMC Cancer Sample , 2015 .

[54]  M. Merad,et al.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.

[55]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[56]  L. Molinero,et al.  T cell-NF-κB activation is required for tumor control in vivo , 2015, Journal of Immunotherapy for Cancer.

[57]  P. Hwu,et al.  Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy , 2014, Clinical Cancer Research.

[58]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[59]  S. Rosenberg Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment , 2014, Nature Reviews Clinical Oncology.

[60]  Y. Nordby,et al.  Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure‐free survival in prostate cancer , 2014, The Prostate.

[61]  K. Hemminki,et al.  Metastatic sites and survival in lung cancer. , 2014, Lung cancer.

[62]  C. Drake,et al.  Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer , 2014, Journal of Immunotherapy for Cancer.

[63]  J. Galon,et al.  Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014, Clinical Cancer Research.

[64]  M. Berger,et al.  Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing , 2014, Molecular Oncology.

[65]  G. Coukos,et al.  CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor , 2013, Clinical Cancer Research.

[66]  Ali Bashashati,et al.  Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.

[67]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[68]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[69]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[70]  E John Wherry,et al.  T cell exhaustion , 2011 .

[71]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[72]  A. Sewell,et al.  Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers , 2009, Journal of immunological methods.

[73]  Surojit Sarkar,et al.  Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates , 2008, The Journal of experimental medicine.

[74]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[75]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[76]  D. Speiser,et al.  Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion , 2015, The EMBO journal.

[77]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[78]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .